Products & Programs PharmacyAnthem Blue Cross and Blue Shield | Medicare AdvantageJanuary 31, 2024

Notification of specialty pharmacy medical step therapy updates

This is a courtesy notice as there is no change to current status of Eylea HD in the Medical Step Therapy Program. The step criteria for anti-vascular endothelial growth factor (VEGF) inhibitors found in Clinical Criteria document CC-0072 will formally list Eylea HD as a preferred product.

Clinical UM Guidelines are publicly available on the provider website. Visit the Clinical Criteria page to search for specific criteria.

Clinical UM GuidelinesPreferred drug(s)Nonpreferred drug(s)
CC-0072Avastin
Byooviz
Cimerli
Eylea
Eylea HD
Lucentis
Vabysmo
Beovu
Macugen

Through genuine collaboration, we can simplify access to care and help you deliver high-quality, equitable healthcare.

Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MEBCBS-CR-046821-23-CPN45766

PUBLICATIONS: March 2024 Provider Newsletter